Pyrimethamine drug interactions: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Pyrimethamine}} {{CMG}}; {{AE}} {{chetan}} ==Drug Interactions== Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other anti...")
 
Line 4: Line 4:


==Drug Interactions==
==Drug Interactions==
Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. However, the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamides or trimethoprim-sulfamethoxazole combinations, proguanil, zidovudine, or cytostatic agents (e.g., methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored (see WARNINGS). Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = DARAPRIM (PYRIMETHAMINE) TABLET [AMEDRA PHARMACEUTICALS LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e4d5027-7939-480f-ae19-82e764d9fa97#nlm34089-3 | publisher =  | date =  | accessdate =  }}</ref>
Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. However, the concomitant use of other antifolic drugs or agents associated with [[myelosuppression]] including sulfonamides or [[trimethoprim-sulfamethoxazole]] combinations, [[proguanil]], [[zidovudine]], or [[cytostatic agents]] (e.g.,[[ methotrexate]]), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid ([[leucovorin]]) should be administered until normal hematopoiesis is restored (see WARNINGS). Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = DARAPRIM (PYRIMETHAMINE) TABLET [AMEDRA PHARMACEUTICALS LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3e4d5027-7939-480f-ae19-82e764d9fa97#nlm34089-3 | publisher =  | date =  | accessdate =  }}</ref>


==References==
==References==

Revision as of 21:40, 9 January 2014

Pyrimethamine
DARAPRIM® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Drug Interactions

Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. However, the concomitant use of other antifolic drugs or agents associated with myelosuppression including sulfonamides or trimethoprim-sulfamethoxazole combinations, proguanil, zidovudine, or cytostatic agents (e.g.,methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. If signs of folate deficiency develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored (see WARNINGS). Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.[1]

References

  1. "DARAPRIM (PYRIMETHAMINE) TABLET [AMEDRA PHARMACEUTICALS LLC]".

Adapted from the FDA Package Insert.